Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
Wall Street Beat
Tandem to submit tubeless pump to FDA with Street-beating Q1 on record pump shipments
Tandem Diabetes Care (Nasdaq:TNDM) today shared its plans to submit a tubeless insulin pump to the FDA. On the company’s first-quarter earnings call, President and CEO John Sheridan outlined the plans for Mobi Tubeless, the company’s existing Mobi pump that utilizes a novel infusion set option for tubeless insulin delivery. Currently, Insulet offers the leading […]
Insulet sales grow 34% in Street-beating Q1 as company ups growth guidance
Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on Wall Street. Shares of PODD ticked up 5% to $175.79 before the market opened today. However, at midday, shares were down 8.2% at $153.78 apiece, potentially in response to scrutiny over U.S. trends and new patient starts. The […]
Embecta ‘disappointed’ with Q2 results that fell below expectations, cuts 2026 guidance
Embecta (Nasdaq:EMBC) today reported second-quarter financial results that fell shy of expectations on Wall Street. The BD Diabetes spinoff attributed shortcomings to increased competitive dynamics and softness in overall market volumes in the U.S. Its international business performed in line with expectations, however. Shares of EMBC fell 43% to $5.29 apiece before the market opened […]
Senseonics amends loan facility, increases borrowing capacity to $140M
Senseonics (NYSE:SENS) announced today that it amended a loan and security agreement to increase its maximum borrowing capacity. The long-term implantable continuous glucose monitor (CGM) maker entered into the agreement with Hercules Capital. It increases its maximum borrowing capacity from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under […]
Dexcom stock dips after hours despite Q1 beats, 15% sales growth
Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months […]
Beta Bionics increases 2026 sales guidance on 57% Q1 growth
Beta Bionics (Nasdaq:BBNX) today reported first-quarter sales results that came in ahead of the forecast on Wall Street. For the full year, the company expects sales to range between $131 million and $136 million. It previously forecast between $130 million and $135 million. Shares of Beta Bionics fell 2% to $12.03 apiece after the market […]
Abbott CEO is bullish on CGM market despite analyst concerns
Abbott (NYSE:ABT) CEO Robert B. Ford remains optimistic about the company’s opportunity in the continuous glucose monitor (CGM) market. The company reported its first-quarter earnings today, which included $2 billion in FreeStyle Libre CGM sales, growing 7.5%. Abbott noted a delay in the renewal process related to an international tender, as well as an expected […]
Analysts initiate MiniMed with ‘Buy’ rating in competitive diabetes tech space
BTIG analysts today opened coverage for MiniMed (Nasdaq:MMED) with optimism about the company’s scale, reach and potential pipeline. Marie Thibault, Alexandra Pang and Sam Eiber initiated MiniMed with a “Buy” rating following the Medtronic Diabetes business’ recent initial public offering (IPO), despite the IPO coming up short of its initial target price. “Our MiniMed Group […]
Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval
Medtronic (NYSE:MDT) said in an SEC filing that it lowered its full-year guidance after a one-time charge related to its MiniMed diabetes unit. Last week, MiniMed announced FDA clearance for the MiniMed Flex, a next-generation automated insulin delivery system. Clearance came “several months earlier than anticipated,” according to the filing, facilitating earlier commercialization. R&D for […]
